Predigen

What Predigen does

Predigen is a privately held for-profit company founded in 2016, headquartered in Durham, North Carolina, with a stated focus on developing host response diagnostics intended for use as prognostic, diagnostic, and therapeutic monitoring tools. The company operates at a micro-scale, with reported headcount of 1-10 employees, and is led by co-founder and CEO Brian Best.

The input data does not contain operational details about Predigen's products, technology stack, clinical pipeline, or commercial customers. The primary source surfaced is a HugeDomains marketplace listing offering the Predigen.com domain for sale at $8,995 (or $374.79/month over 24 months), indicating that the company's web presence is no longer being actively maintained through this domain. There is no evidence in the input of active revenue-generating operations, disclosed funding, partnerships, patents, or regulatory milestones. The company's current operating status, product portfolio, and go-to-market mechanics cannot be substantiated from the available information.

Name

Predigen

Website

https://www.predigen.com/

Company type

Private

Founded year

2016

Headcount range

1–10 employees

Short description

Predigen is a privately held diagnostics company founded in 2016 in Durham, North Carolina, that was described as developing host response diagnostics for prognostic, diagnostic, and therapeutic monitoring applications. Current operating status and commercial activity are not evidenced in the available data.

Ownership category

akta.pro rank

Product category

Clinical Diagnostics

NAICS

Medical Laboratories (621511)

SIC

In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

Molecular Diagnostics & Genomics Laboratories (HLAFAMAE)

akta.pro secondary industries

Genomics & Molecular Diagnostics (Trial Support) (HLAGAEAD), Proteomics & Biomarker Analytical Testing (HLAGADAG)

Keywords

• Host response diagnostics
• Clinical diagnostics
• Prognostic biomarkers
• Therapeutic monitoring
• Diagnostic test development

Headquarters

HQ city

Durham

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations

Pricing tiers

Distribution channels1 record

Core offering

Predigen develops host response diagnostics for use as prognostic, diagnostic, and therapeutic monitoring tools. The company is positioned within the clinical diagnostics segment, applying biomarker-based analysis of the host response to support disease assessment and treatment monitoring for healthcare and research customers.

Product overview

Predigen.com is currently a domain name listed for sale, not an active company or product. The domain 'Predigen' (8 characters) with .com TLD is being offered for $8,995 or via payment plan ($374.79/month for 24 months) through HugeDomains, a domain marketplace. No product, service, or company information exists for Predigen beyond the domain sale listing.

Differentiator

Problem solved

Functional benefit

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Recent moves1 record

Expansion highlights1 record

Direct peers

• Inflammatix: Inflammatix develops host-response (immune-gene-expression) diagnostics for acute infection and sepsis triage, directly matching Predigen's stated host-response diagnostic focus and target use cases.
• Immunexpress: Immunexpress commercializes host-response-based molecular diagnostics (SeptiCyte) for sepsis, making it one of the closest direct competitors in the host-response diagnostic category.
• Cytovale: Cytovale's IntelliSep is a host-response cellular biomarker test for sepsis diagnosis in the ED, a directly overlapping product, customer, and clinical use case.

Broad incumbents

• bioMérieux: bioMérieux is a global diagnostics incumbent with a deep molecular diagnostics and microbiology portfolio serving hospitals and labs, including host-response-adjacent sepsis and antimicrobial-stewardship applications.
• Cepheid (Danaher): Cepheid's GeneXpert platform is a broadly installed molecular diagnostics system in U.S. hospitals; it competes for the same hospital lab budget and clinical-decision use cases that a host-response test would target.
• Qiagen: Qiagen supplies sample-prep and PCR-based molecular diagnostic technologies used in host-response and infectious-disease workflows, making it an incumbent enabling/competing player.
• Hologic: Hologic's diagnostic division (e.g., Panther system, sepsis-adjacent assays) overlaps with Predigen's hospital-based molecular diagnostic commercial channel and customer base.
• Roche Diagnostics: Roche Diagnostics operates one of the largest hospital-based molecular diagnostics portfolios globally and competes for the same clinical-decision and lab-budget dollars as a host-response diagnostic.

Emerging players

• T2 Biosystems: T2 Biosystems develops molecular diagnostics for sepsis and other bloodstream-based conditions; smaller and more narrowly focused than bioMérieux or Cepheid, but addressing a directly overlapping clinical indication.
• DxTerity: DxTerity is a molecular diagnostics company focused on gene-expression-based tests for immune-mediated and infectious conditions, partially overlapping with Predigen's host-response approach.

Market position

Strengths3 records

Weaknesses4 records

Competitive moat1 record

Key risks5 records

Key highlights4 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Predigen